Aiforia closes a deal with a major pharmaceutical company – reaches its short-term business target of acquiring ten large customers in the pharmaceutical industry

Aiforia Technologies Plc, Press Release, 3 May 2023 at 02:00 p.m. EEST. Aiforia has signed an agreement with one of the world’s top-rated pharmaceutical companies to collaborate in AI-assisted image analysis.

Together the two aim to develop deep-learning models for tissue sample analysis. With this deal, Aiforia has reached its short-term business target of acquiring ten large customers in the pharmaceutical industry by the end of 2023. Aiforia’s short- and medium-term business targets were set at the time of the initial public offering in 2021.

“This is yet another proof that Aiforia’s AI solutions can help pharmaceutical companies to increase the speed, accuracy, and consistency of research and development workflows,” says Jukka Tapaninen, CEO of Aiforia. “Collaborations with pharmaceutical companies are an essential part of our growth strategy. I am pleased to see how we have been able to develop our business according to the plan and achieve this target well before the end of the year.”

Further inquiries

Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686
https://investors.aiforia.com/ 

Certified Adviser

UB Securities Ltd, tel. +358 9 25 380 225 

About Aiforia

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep-learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud-based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities across various fields, from oncology to neuroscience and more. Find out more at  www.aiforia.com